Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?

Transplantation Proceedings

Volumn 42, Issue 9 SUPPL., 2010, Pages

  Geissler, E K ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; GROWTH FACTOR; ION CHANNEL; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID; RAPAMYCIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA DAMAGE; DRUG SUBSTITUTION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKEMIA; MEMORY T LYMPHOCYTE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SKIN CANCER; TUBEROUS SCLEROSIS; TUMOR GROWTH;

EID: 78649434592     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.07.004     Document Type: Article

References (22)

1. I. Penn Cancers complicating organ transplantation N Engl J Med 323 1990 1767
2. A.C. Webster, J.C. Craig, and J.M. Simpson Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15 183 recipients Am J Transplant 7 2007 2140
3. A.E. Grulich, M.T. van Leeuwen, and M.O. Falster Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis Lancet 370 2007 59
4. M. Hojo, T. Morimoto, and M. Maluccio Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530
5. M. Herman, T. Weinstein, and A. Korzets Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients J Lab Clin Med 137 2001 14
6. G. Koehl, J. Andrassy, and M. Guba Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice Transplantation 77 2004 1319
7. M. Guba, P. von Breitenbuch, and M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128
8. J. Dantal, and J.P. Soulillou Immunosuppressive drugs and the risk of cancer after organ transplantation N Engl J Med 352 2005 1371
9. G. Koehl, F. Wagner, and O. Stoeltzing MMF inhibits tumor growth and angiogenesis in vitro, but has variable anti-tumor effects in vivo possibly related to bioavailability Transplantation 83 2007 607
10. R. Robson, J.M. Cecka, and G. Opelz Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil Am J Transplant 5 2005 2954
11. F.L. Luan, M. Hojo, and M. Maluccio Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy Transplantation 73 2002 1565
12. E.K. Geissler, H.J. Schlitt, and G. Thomas mTOR, cancer and transplantation Am J Transplant 8 2008 2212
13. min/+ mice Oncogene 29 2010 1553
14. F.R. de Gruijl, G.E. Koehl, and P. Voskamp Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis Int J Cancer Dec 8, 2009 (Epub ahead of print)
15. + T regulatory cells and promote organ transplant tolerance J Immunol 178 2007 7018
16. + T cells Blood 111 2008 453
17. + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin Immunity 32 2010 67
18. H.M. Kauffman, W.S. Cherikh, and Y. Cheng Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883
19. G. Stallone, A. Schena, and B. Infante Sirolimus for Kaposi's sarcoma in renal-transplant recipients N Engl J Med 352 2005 1317
20. J.M. Campistol, A. Gutierrez-Dalmau, and J.V. Torregrosa Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma Transplantation 77 2004 760
21. F.P. Schena, M.D. Pascoe, and J. Alberu Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233
22. R. Salgo, J. Gossmann, and H. Schfer Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial Am J Transplant 10 2010 1